Literature DB >> 11727407

Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus.

A A Taylor1.   

Abstract

There is compelling evidence for endothelial dysfunction in both type 1 and type 2 diabetics. This dysfunction is manifest as blunting of the biologic effect of a potent endothelium-derived vasodilator, nitric oxide, and increased production of vasoconstrictors such as angiotensin II, ET-1, and cyclooxygenase and lipoxygenase products of arachidonic acid metabolism. These agents and other cytokines and growth factors whose production they stimulate cause acute increases in vascular tone, resulting in increases in blood pressure, and vascular and cardiac remodeling that contributes to the microvascular, macrovascular, and renal complications in diabetes. Reactive oxygen species, overproduced in diabetics, serve as signaling molecules that mediate many of the cellular biochemical reactions that result in these deleterious effects. Adverse vascular consequences associated with endothelial dysfunction in diabetes mellitus are Decreased nitric oxide formation, release, and action Increased formation of reactive oxygen species Decreased prostacyclin formation and release Increased formation of vasoconstrictor prostanoid Increased formation and release of ET-1 Increased lipid oxidation Increased cytokine and growth factor production Increased adhesion molecule expression Hypertension Changes in heart and vessel wall structure Acceleration of the atherosclerotic process Treatment with antioxidants and with inhibitors of the renin-angiotensin system may reverse some of the pathologic vascular changes associated with endothelial dysfunction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11727407     DOI: 10.1016/s0889-8529(05)70223-1

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  12 in total

Review 1.  Hypertension and atherosclerosis: clinical implications from the ALLHAT Trial.

Authors:  John B Standridge
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

2.  CD36 protein is involved in store-operated calcium flux, phospholipase A2 activation, and production of prostaglandin E2.

Authors:  Ondrej Kuda; Christopher M Jenkins; James R Skinner; Sung Ho Moon; Xiong Su; Richard W Gross; Nada A Abumrad
Journal:  J Biol Chem       Date:  2011-03-31       Impact factor: 5.157

Review 3.  Vascular reactivity in diabetes mellitus.

Authors:  Ajay Chaudhuri
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

Review 4.  Endothelium, inflammation, and diabetes.

Authors:  Paresh Dandona
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

5.  Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, alphavbeta3-integrin, and TGF-beta1 in response to ANG II and high glucose.

Authors:  Souad Belmadani; Mourad Zerfaoui; Hamid A Boulares; Desiree I Palen; Khalid Matrougui
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

Review 6.  Metformin: new understandings, new uses.

Authors:  Ripudaman S Hundal; Silvio E Inzucchi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic.

Authors:  R J King; P J Grant
Journal:  Herz       Date:  2016-05       Impact factor: 1.443

Review 8.  Eicosanoids and renal damage in cardiometabolic syndrome.

Authors:  John D Imig
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-02       Impact factor: 4.481

Review 9.  Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.

Authors:  Clarissa Cola; Salvatore Brugaletta; Victoria Martín Yuste; Bieito Campos; Dominick J Angiolillo; Manel Sabaté
Journal:  Vasc Health Risk Manag       Date:  2009-04-08

Review 10.  Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme.

Authors:  Luis Miguel Ruilope; Josep Redón; Roland Schmieder
Journal:  Vasc Health Risk Manag       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.